Today’s Highlights- Prohost Biotech - Exclusive Biotech Research

Category: Today’s Highlights

bluebird bio Provides Updated Findings of AML in LentiGlobin for SCD Gene Therapy Program

Updated Findings from bluebird bio bluebird bio analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in a clinical study of LentiGlobin for SCD bluebird bio initiated a process with regulators to resume clinical studies bluebird bio (...

March 10, 2021

Karyopharm Therapeutics: CHMP Recommended Approval of the Firm's Product NEXPOVIO® for Multiple Melanoma in Europe.

Karyopharm Therapeutics Karyopharm Therapeutics ( KPTI ) and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, announced that the European Medicines Agency's ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a...

May 20, 2022

Merck: KEYTRUDA Plus Chemo as First-Line Treatment for Stage III-IV or Recurrent Endometrial Carcinoma

Merck KEYTRUDA Announcement Merck ( MRK ) announced today that Phase 3 NRG-GY018 trial evaluating KEYTRUDA in combination with chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival ( PFS ) in patients with stage III-IV or recurrent...

February 3, 2023

Vir Biotechnology and GlaxoSmithKline: Independent Data Monitoring Committee Recommends Stopping Phase 3 COMET-ICE Trial Early

Vir Biotechnology and GlaxoSmithKline Recommended to Stop Phase 3 COMET-ICE Trial Vir Biotechnology ( VIR ) and GlaxoSmithKline ( GSK ) announced that an Independent Data Monitoring Committee ( IDMC ) recommended that the Phase 3 COMET-ICE trial - the...

March 11, 2021

Anixa Biosciences: Why This Firm Outperformed Today

Anixa Biosciences Outperformance Anixa Biosciences Inc ( ANIX ) is the worldwide licensee of a patent technology titled "Ovarian Cancer Vaccine" which was created at Cleveland Clinic. Anixa Therapeutics specializes in the treatment and prevention of cancer and infectious diseases....

March 12, 2021

Gilead Sciences and Merck: Long-Term Oral HIV Combination Treatment

Gilead Sciences and Merck Announced Agreement for Long-Term HIV Combination Treatment Gilead Sciences ( GILD ) and Merck ( MRK ) announced that they have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s...

March 15, 2021

Why Travere Therapeutics' Stocks Did Not Fall During This Tuesday's Bad Market

The Bear Market The volatility in the Bear stock market continues to plunge the values of biotech stocks. The Bear market is sucking investors’ capitals who bet on firms with future growth potential based on early, mid term and late...

February 22, 2023

Regeneron: The Completed Acquisition of Checkmate Pharmaceuticals is Excellent News Not Bad News

Regeneron Pharmaceuticals Acquisition of Checkmate Pharmaceuticals Regeneron Pharmaceuticals ( REGN ) announced a successful acquisition of Checkmate Pharmaceuticals, Inc., deepening its commitment to immuno-oncology. The firm has added a new modality to the company's portfolio of potential combination-ready approaches for...

May 31, 2022

Intellia Therapeutics Announces FDA Clearance of IND Application for NTLA-2002 Therapy for the Treatment of Hereditary Angioedema

Intellia Therapeutics Intellia Therapeutics ( NTLA ) announced that the U.S. FDA has cleared the company’s Investigational New Drug ( IND ) application for NTLA-2002. About NTLA-2002 Based on Nobel Prize-winning CRISPR/Cas9 technology, NTLA-2002 is the first single-dose investigational treatment. NTLA-2002...

March 2, 2023

AstraZeneca to Supply Half a Million Additional Doses of the Potential COVID-19 Antibody Treatment AZD7442 to the U.S.

AstraZeneca to Supply Additional Doses of AZD7442 to the U.S. for COVID-19 AstraZeneca ( AZN ) has modified an existing agreement with the U.S. Government to supply up to 500,000 additional doses of AZD7442 - a long-acting antibody ( LAAB...

March 17, 2021

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024